Angle Closure Glaucoma
Sandra Fernando Sieminski
Sanjay Mohan
THE CLINICAL CHALLENGE
Angle closure is a process that results from appositional closure of the iridocorneal angle, or drainage angle of the eye, leading to aqueous humor outflow obstruction and consequent increase in intraocular pressure (IOP). This increase in IOP can lead to progressive optic nerve damage and peripheral vision loss, which is a disease state known as glaucoma. Primary angle-closure (PAC) occurs when obstruction is a result of anatomic predisposition of the eye to have crowding of the angle, usually owing to a small eye or a large cataract. Secondary angle-closure is attributable to a coexisting ocular disease process (eg, inflammation, tumor, or hemorrhage), which causes physical occlusion of the angle owing to debris or scar tissue formation in the angle. In the United States, although more than 80% of glaucoma cases are open-angle in etiology, angle closure glaucoma accounts for a disproportionate number of patients with severe vision loss and thus accounts for more emergency department (ED) visits.1
The prevalence of angle closure glaucoma varies considerably among ethnic and racial groups. Inuit and Asian populations account for the highest rates, whereas lower rates are reported in African and European populations.2 Other risk factors include female gender, farsightedness (hyperopia), having a shallow anterior chamber, use of medications that can induce angle narrowing (eg, pupil dilators, including alpha agonists and anticholinergic agents), advanced age (most common between ages of 55 and 65), cataracts, and family history.2
The challenge of this disease primarily posits in prevention and diagnosis. Much like open-angle glaucoma, closed-angle glaucoma is typically an asymptomatic disease process in which patients are unaware of this illness until advanced visual loss occurs. Whereas acute angle closure glaucoma presents with a change in vision or with severe acute symptoms, chronic angle closure glaucoma tends to be discovered incidentally.
Clinical presentation and symptoms result from the rapidity and degree of IOP elevation. Acute angle glaucoma is suggested by severe ocular or periocular pain, decreased vision, halos around lights, headache, nausea, and vomiting. In contrast, chronic angle glaucoma patients are asymptomatic because the rise in IOP is gradual and less severe.
PATHOPHYSIOLOGY
The distinguishing feature of angle closure glaucoma is that the iridocorneal angle, the junction between the iris and the cornea, which functions as the site of aqueous humor outflow, is obstructed. The most common cause of primary angle closure is referred to as “pupillary block.” In order to understand the pathophysiology involved with pupillary block, it is important to understand the flow of aqueous in a nondiseased state (Figure 47.1). Aqueous humor is secreted from the ciliary body, a circumferential structure located behind the iris in the posterior chamber of the eye, and flows through the pupil to the anterior chamber of the eye. Eventually, the aqueous humor exits the
anterior chamber through the iridocorneal angle, which is composed of multiple layers of tissue. The most superficial layer is called the trabecular meshwork, a sievelike tissue with the deepest layer, called the canal of Schlemm. Through the canal of Schlemm, the aqueous humor ultimately drains into the venous system.
anterior chamber through the iridocorneal angle, which is composed of multiple layers of tissue. The most superficial layer is called the trabecular meshwork, a sievelike tissue with the deepest layer, called the canal of Schlemm. Through the canal of Schlemm, the aqueous humor ultimately drains into the venous system.
In pupillary block, the flow of aqueous humor from posterior to anterior chamber is blocked at the pupil, typically because there is contact between the lens and the iris. As the lens opacifies and grows with age (ie, cataract), the propensity of pupillary block to occur increases. As the aqueous accumulates behind the iris, the pressure in the posterior chamber increases, causing the iris to bow anteriorly, creating an outlet obstruction and perpetuating the cycle of angle closure.
Outside of pupillary block, the etiology of angle closure glaucoma can be subdivided into three other groups: physiologic crowding of the angle, lens induced, and plateau iris syndrome.3 Crowded angle tends to occur in patients with thicker iris tissue. In these cases, there is less space for aqueous humor to drain through the trabecular meshwork. With pupillary dilation, the iris is pulled peripherally and further crowds the iridocorneal angle. Lens-induced angle closure can occur either when a large, mature cataract pushes the iris forward and closes the angle or when the lens is subluxed anteriorly. In both cases, there may still be an element of pupillary block owing to the lens-iris contact, but the primary mechanism of angle closure is anterior displacement of the iris by the lens. In lens subluxation, the zonules, ligaments that suspend the lens in its anatomic position behind the iris, are loosened and cause the lens to displace anteriorly. Predisposing conditions for lens subluxation include trauma, Marfan syndrome, Ehlers-Danlos syndrome, and homocystinuria. Plateau iris syndrome is defined by an anterior insertion of the peripheral iris base onto the ciliary body. This positioning of the iris can cause narrowing of the iridocorneal angle that is not caused by pupillary block and can present as acute or chronic angle closure.3
Medication-induced angle closure glaucoma can be accounted for by a variety of mechanisms (pupillary block via miosis, angle crowding with mydriasis, and iridocorneal angle disruption secondary to ciliochoroidal effusion). Alpha-adrenergic agonists are mydriatic agents that are routinely administered by ophthalmologists and optometrists for pupillary dilation and funduscopic examination and are also found in a variety of over-the-counter cold and allergy medicines such as decongestants. Mydriasis induces thickening at the base of the iris that can potentially generate iridotrabecular contact and angle closure acutely. Anticholinergic agents such as atropine, tropicamide, and cyclopentolate target different muscles; however, all result in pupillary dilation and iridocorneal angle closure. Other medications that may precipitate angle closure glaucoma include beta2 agonists, sulfonamide containing medications such as topiramate and trimethoprim-sulfamethoxazole, anticoagulants such as heparin and warfarin, and certain serotonergic agents.4
APPROACH/THE FOCUSED EXAM
In approaching a patient with suspected angle closure, it is important to elicit a thorough history. This includes history of eye surgery, medications, recent medical procedures, recent facial trauma, contact lens use, eye drop use, and prior occurrences of eye pain and/or redness. Patients may endorse symptoms such as halos around lights, blurry vision, headache over the brow, and nausea. Their symptom onset can be linked to starting a new medication or entering a dimly lit room, which causes pupillary dilation.4
As with any ocular pathology, visual acuity should be assessed. Given the degree of pain and discomfort, the patient may be unable to read letters on a Snellen chart, and if so, it should be determined whether the patient can count fingers or perceive hand movements or light. On gross inspection, the patient will classically present with a unilateral red eye, a fixed mid-dilated pupil, and some degree of corneal clouding secondary to edema.4 There can also be focal redness surrounding the limbus (the junction between the cornea and the sclera), pigment granules or white flecks on the anterior surface of the cataract, iris atrophy or transillumination caused by iris ischemia from high IOP if this is not the patient’s first episode of angle closure, and a shallow anterior chamber (the space between the cornea and the iris). Many of these features are seen in Figure 47.2 of a patient presenting in angle closure after receiving laser iridotomy.